Colobreathe is a brand name for the antibiotic medication known as colistimethate sodium, which is specifically designed for inhalation use. It is primarily prescribed for the management and treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis. Colobreathe works by targeting and killing the bacteria responsible for the infection, helping to improve lung function and reduce the frequency of exacerbations associated with the disease. This medication comes in the form of dry powder for inhalation, and it is typically used in conjunction with a specialized inhaler device provided with the medication. Colobreathe offers a targeted approach to treating lung infections, making it a valuable option for individuals with cystic fibrosis seeking to manage their condition effectively.